Boehringer Ingelheim has extended research funding for another year in its Alzheimer’s disease collaboration with Ablynx. In January 2007 the companies entered into a $265 million worldwide research and licensing agreement to discover and develop new therapies for Alzheimer’s disease using Ablynx’s Nanobodies, a class of therapeutic proteins. The agreement included a joint research program with Ablynx scientists. BI will be responsible for the development, manufacture and co...